

1 Association of Structural Forms of 17q21.31 with the Risk of Progressive 2 Supranuclear Palsy and *MAPT* Sub-haplotypes

3 Hui Wang^{1,2}, PhD; Timothy S Chang³, MD, PhD; Beth A Dombroski^{1,2}, PhD; Po-Liang Cheng^{1,2}, PhD;
4 Ya-Qin Si⁴, PhD; Albert Tucci⁴, PhD; Vishakha Patil⁵, MS; Leopoldo Valiente-Banuet⁵, MS; Kurt
5 Farrell⁶, PhD; Catriona Mclean⁷, MD; Laura Molina-Porcel^{8,9}, MD, PhD; Alex Rajput¹⁰, MD; Peter Paul
6 De Deyn^{11,12}, MD, PhD; Nathalie Le Bastard¹³, PhD; Marla Gearing¹⁴, PhD; Laura Donker Kaat¹⁵, MD,
7 PhD; John C Van Swieten¹⁵, MD, PhD; Elise Dopper¹⁵, MD, PhD; Bernardino F Ghetti¹⁶, MD; Kathy L
8 Newell¹⁶, MD; Claire Troakes¹⁷, PhD; Justo G de Yébenes¹⁸, MD, PhD; Alberto Rábano-Gutierrez¹⁹,
9 MD, PhD; Tina Meller²⁰, PhD; Wolfgang H Oertel²⁰, MD, PhD; Gesine Respondek²¹, MD; Maria
10 Stamelou^{22,23}, MD; Thomas Arzberger^{24,25}, MD; Sigrun Roeber²⁶, MD; Ulrich Müller²⁶, MD; Franziska
11 Hopfner⁴⁴, MD; Pau Pastor^{27,28}, MD, PhD; Alexis Brice²⁹, MD; Alexandra Durr²⁹, MD, PhD; Isabelle Le
12 Ber²⁹, MD, PhD; Thomas G Beach³⁰, MD, PhD; Geidy E Serrano³⁰, PhD; Lili-Naz Hazrati³¹, MD, PhD;
13 Irene Litvan³², MD; Rosa Rademakers^{33,34}, PhD; Owen A Ross³⁴, PhD; Douglas Galasko³², MD; Adam
14 L Boxer³⁵, MD, PhD; Bruce L Miller³⁵, MD; Willian W Seeley³⁵, MD; Vivianne M Van Deerlin¹, MD,
15 PhD; Edward B Lee^{1,36}, MD, PhD; Charles L White III³⁷, MD; Huw R Morris³⁸, MD, PhD; Rohan de
16 Silva³⁹, PhD; John F Crary⁶, MD, PhD; Alison M Goate⁴⁰, PhD; Jeffrey S Friedman⁴¹, MD, PhD; Yuk
17 Yee Leung^{1,2}, PhD; Giovanni Coppola^{5,42}, MD; Adam C Naj^{1,2,43}, PhD; Li-San Wang^{1,2}, PhD; PSP
18 genetics study group; Dennis W Dickson³⁴, MD; Günter U Höglinger⁴⁴, MD; Jung-Ying Tzeng^{4,45}, PhD;
19 Daniel H Geschwind^{5,46,47}, MD, PhD; Gerard D Schellenberg^{1,2}, PhD; Wan-Ping Lee^{1,2}, PhD

20

21 ¹Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of
22 Pennsylvania, Philadelphia, PA, USA

23 ²Penn Neurodegeneration Genomics Center, Perelman School of Medicine, University of Pennsylvania,
24 Philadelphia, PA, USA

25 ³Movement Disorders Programs, Department of Neurology, David Geffen School of Medicine,
26 University of California, Los Angeles, Los Angeles, CA, USA

27 ⁴Bioinformatics Research Center, North Carolina State University, NC, USA

28 ⁵Movement Disorders Programs, Department of Neurology, David Geffen School of Medicine,
29 University of California, Los Angeles, Los Angeles, CA, USA

- 30 ⁶Department of Pathology, Department of Artificial Intelligence & Human Health, Nash Family,
31 Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain,
32 Institute, Neuropathology Brain Bank & Research CoRE, Icahn School of Medicine at Mount Sinai,
33 New York, NY, USA.
- 34 ⁷Victorian Brain Bank, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria,
35 Australia
- 36 ⁸Alzheimer's disease and other cognitive disorders unit. Neurology Service, Hospital Clínic,
37 Fundació Recerca Clínic Barcelona (FRCB). Institut d'Investigacions Biomediques August Pi i Sunyer
38 (IDIBAPS), University of Barcelona, Barcelona, Spain
- 39 ⁹Neurological Tissue Bank of the Biobanc-Hospital Clínic-IDIBAPS, Barcelona, Spain
- 40 ¹⁰Movement Disorders Program, Division of Neurology, University of Saskatchewan, Saskatoon,
41 Saskatchewan, Canada
- 42 ¹¹Laboratory of Neurochemistry and Behavior, Experimental Neurobiology Unit, University of Antwerp,
43 Wilrijk (Antwerp), Belgium
- 44 ¹²Department of Neurology, University Medical Center Groningen, NL-9713 AV Groningen,
45 Netherlands
- 46 ¹³Fujirebio Europe NV, Technologiemarkt 6, 9052 Gent, Belgium
- 47 ¹⁴Department of Pathology and Laboratory Medicine and Department of Neurology, Emory University
48 School of Medicine, Atlanta, GA, USA
- 49 ¹⁵Netherlands Brain Bank and Erasmus University, Netherlands
- 50 ¹⁶Department of Pathology and Laboratory Medicine, Indiana University School of Medicine,
51 Indianapolis, IN, USA
- 52 ¹⁷London Neurodegenerative Diseases Brain Bank, King's College London, London, UK
- 53 ¹⁸Autonomous University of Madrid, Madrid, Spain
- 54 ¹⁹Fundación CIEN (Centro de Investigación de Enfermedades Neurológicas) - Centro Alzheimer
55 Fundación Reina Sofía, Madrid, Spain
- 56 ²⁰Department of Neurology, Philipps-Universität, Marburg, Germany
- 57 ²¹German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- 58 ²²Parkinson's disease and Movement Disorders Department, HYGEIA Hospital, Athens, Greece
- 59 ²³European University of Cyprus, Nicosia, Cyprus
- 60 ²⁴Department of Psychiatry and Psychotherapy, University Hospital Munich,
61 Ludwig-Maximilians-University Munich, Germany
- 62 ²⁵Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Germany
- 63 ²⁶German Brain Bank, Neurobiobank Munich, Germany
- 64 ²⁷Unit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias i
65 Pujol, Badalona, Barcelona, Spain
- 66 ²⁸Neurosciences, The Germans Trias i Pujol Research Institute (IGTP) Badalona, Badalona, Spain
- 67 ²⁹Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR
68 7225, APHP - Hôpital Pitié-Salpêtrière, Paris, France

69 ³⁰Banner Sun Health Research Institute, Sun City, AZ, USA

70 ³¹University McGill, Montreal, Quebec, Canada

71 ³²Department of Neuroscience, University of California, San Diego, CA, USA

72 ³³VIB Center for Molecular Neurology, University of Antwerp, Belgium

73 ³⁴Department of Neuroscience, Mayo Clinic Jacksonville, FL, USA

74 ³⁵Memory and Aging Center, University of California, San Francisco, CA, USA

75 ³⁶Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine,
76 Philadelphia, PA, USA

77 ³⁷University of Texas Southwestern Medical Center, Dallas, TX, USA

78 ³⁸Departmento of Clinical and Movement Neuroscience, University College of London, London, UK

79 ³⁹Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.

80 ⁴⁰Department of Genetics and Genomic Sciences, New York, NY, USA; Icahn School of Medicine at
81 Mount Sinai, New York, NY, USA

82 ⁴¹Friedman Bioventure, Inc., Del Mar, CA, USA

83 Department of Genetics and Genomic Sciences, New York, NY, USA

84 ⁴²Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, University of
85 California, Los Angeles, CA, USA

86 ⁴³Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University
87 of Pennsylvania, Philadelphia, PA, USA

88 ⁴⁴Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU)
89 München; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; and Munich
90 Cluster for Systems Neurology (Synergy), Munich, Germany

91 ⁴⁵Department of Statistics, North Carolina State University, NC, USA

92 ⁴⁶Department of Human Genetics, David Geffen School of Medicine, University of California, Los
93 Angeles, Los Angeles, CA, USA

94 ⁴⁷Institute of Precision Health, University of California, Los Angeles, Los Angeles, CA, USA

95

96 **Search Terms:**

97 Progressive Supranuclear Palsy (PSP), H1 and H2 haplotypes, MAPT, Copy number variation (CNV),
98 17q21.31

99

100 **Word Count:** 3902 (Key Points, Abstract, and Main Text)

101

102 **Corresponding Author:**

103 Wan-Ping Lee

104 D103 Medical Research Laboratories, University of Pennsylvania,

105 3700 Hamilton Walk, Philadelphia, PA 19104, USA

106 Phone: +1 412-880-8674

107 Email: wan-ping.lee@pennmedicine.upenn.edu

108

109 **Statistical Analysis** conducted by Hui Wang, Ph.D., University of Pennsylvania

110 **Key Points**

111 **Question:** Do large copy number variations (i.e., α , β , and γ) inside 17q21.31 contribute to the risk of
112 progressive supranuclear palsy (PSP) independently from the H1 and H2 haplotypes? Do structural
113 forms of 17q21.31, characterized by combinations of α , β , and γ , present divergent risk to the
114 development of PSP? Are structural forms of 17q21.31 associated with *MAPT* sub-haplotypes, such as
115 H1c?

116 **Findings:** In this case-control study of 1,684 individuals with PSP and 2,392 control subjects, the copy
117 number of γ duplication was independently associated with the risk of the disease. H1 haplotypes with
118 more γ duplications (H1 β 1 γ 2, H1 β 1 γ 3, and H1 β 1 γ 4) displayed a higher odds ratio for PSP when
119 compared to H1 β 1 γ 1. Notably, H1 β 1 γ 3 was observed to be in linkage disequilibrium with H1c, a widely
120 recognized *MAPT* sub-haplotype associated with PSP.

121 **Meaning:** The association between the H1 and H2 haplotypes and PSP involves multiple contributing
122 factors, including the copy number of γ duplication.

123 **Abstract**

124 **Importance:** The chromosome 17q21.31 region, containing a 900 Kb inversion that defines H1 and H2
125 haplotypes, represents the strongest genetic risk locus in progressive supranuclear palsy (PSP). In
126 addition to H1 and H2, various structural forms of 17q21.31, characterized by the copy number of α , β ,
127 and γ duplications, have been identified. However, the specific effect of each structural form on the risk
128 of PSP has never been evaluated in a large cohort study.

129

130 **Objective:** To assess the association of different structural forms of 17q.21.31, defined by the copy
131 numbers of α , β , and γ duplications, with the risk of PSP and *MAPT* sub-haplotypes.

132

133 **Design, setting, and participants:** Utilizing whole genome sequencing data of 1,684 (1,386 autopsy
134 confirmed) individuals with PSP and 2,392 control subjects, a case-control study was conducted to
135 investigate the association of copy numbers of α , β , and γ duplications and structural forms of 17q21.31
136 with the risk of PSP. All study subjects were selected from the Alzheimer's Disease Sequencing Project
137 (ADSP) Umbrella NG00067.v7. Data were analyzed between March 2022 and November 2023.

138

139 **Main outcomes and measures:** The main outcomes were the risk (odds ratios [ORs]) for PSP with 95%
140 CIs. Risks for PSP were evaluated by logistic regression models.

141

142 **Results:** The copy numbers of α and β were associated with the risk of PSP only due to their correlation

143 with H1 and H2, while the copy number of γ was independently associated with the increased risk of
144 PSP. Each additional duplication of γ was associated with 1.10 (95% CI, 1.04-1.17; $P = 0.0018$) fold of
145 increased risk of PSP when conditioning H1 and H2. For the H1 haplotype, addition γ duplications
146 displayed a higher odds ratio for PSP: the odds ratio increases from 1.21 (95%CI 1.10-1.33, $P = 5.47 \times$
147 10^{-5}) for H1 β 1 γ 1 to 1.29 (95%CI 1.16-1.43, $P = 1.35 \times 10^{-6}$) for H1 β 1 γ 2, 1.45 (95%CI 1.27-1.65, $P =$
148 3.94×10^{-8}) for H1 β 1 γ 3, and 1.57 (95%CI 1.10-2.26, $P = 1.35 \times 10^{-2}$) for H1 β 1 γ 4. Moreover, H1 β 1 γ 3 is
149 in linkage disequilibrium with H1c ($R^2 = 0.31$), a widely recognized *MAPT* sub-haplotype associated
150 with increased risk of PSP. The proportion of *MAPT* sub-haplotypes associated with increased risk of
151 PSP (i.e., H1c, H1d, H1g, H1o, and H1h) increased from 34% in H1 β 1 γ 1 to 77% in H1 β 1 γ 4.

152 **Conclusions and relevance:** This study revealed that the copy number of γ was associated with the risk
153 of PSP independently from H1 and H2. The H1 haplotype with more γ duplications showed a higher
154 odds ratio for PSP and were associated with *MAPT* sub-haplotypes with increased risk of PSP. These
155 findings expand our understanding of how the complex structure at 17q21.31 affect the risk of PSP.

156 **Introduction**

157 Progressive supranuclear palsy (PSP) is a neurodegenerative disease with two characteristic clinical
158 features, i.e. postural instability and ocular motor abnormalities¹. Other symptoms and signs, such as
159 cognitive dysfunction and problems with swallowing, vary and can get worse over time depending on the
160 distribution of pathology and severity of diseases^{2,3}. The main pathology of PSP is the accumulation of
161 tau in the brain, leading to the presence of neurofibrillary tangles and threads along with tufted
162 astrocytes and oligodendroglial coiled bodies^{4,5}. An isoform of tau harboring 4 repeats (4R) of
163 microtubule-binding domain is particularly prominent in these tau aggregates⁶.

164 The most recognized genetic risk locus for PSP is situated on 17q21.31. The region can be divided
165 into two major haplotypes, H1 and H2, characterized by a 900 Kb inversion found in 20% of Europeans⁷.
166 Individuals carrying the H1 haplotype, compared to the H2 haplotype, are more likely to develop PSP,
167 with an estimated odds ratio (OR) around 5 in Europeans^{8,9}. The association was identified through
168 various variants in linkage disequilibrium (LD) with H1 and H2, such as a dinucleotide repeat (TG)_n in
169 *MAPT* intron 9¹⁰, a 238-bp deletion in *MAPT* intron 9⁷, and a multitude of single nucleotide variants
170 (SNVs) in this region^{8,9}. However, the causal variants underlying the association remain unclear due to
171 numerous SNVs, short insertion/deletions (indels), and structural variations (SVs) introduced by
172 complex genomic rearrangements in 17q.21.31.

173 Based on LD structure in the *MAPT* region, H1 and H2 haplotypes can be further categorized into
174 more than 20 common sub-haplotypes¹¹⁻¹³. Among them, H1c, H1d, H1g, and H1o were significantly
175 associated with the increased risk of PSP^{11,13}. Particularly, H1c and H1d are nominally associated with

176 measures of severity of tau pathology in PSP cases¹¹. However, these sub-haplotypes were inferred from
177 LD structure limited to *MAPT* gene (~150 Kb) and do not represent the intricacies of structural forms on
178 17q21.31 (~1.5 Mb). To address this limitation, we constructed the ten structural forms of 17q21.31,
179 characterized by the copy numbers of α , β , and γ (150Kb, 300Kb, and 218Kb; eFigure 1 in
180 **Supplement**)^{14,15}, and evaluated their association with the risk of PSP in this study. We found that the
181 H1 haplotype with more copies γ duplication showed an increased risk of PSP. The result is in
182 accordance with the higher portion of H1c and other *MAPT* sub-haplotypes associated with increased
183 risk of PSP in the H1 haplotypes with more copies of γ . Through this study, we gained a better
184 understanding how the haplotypic structure of 17q.21.31 correlates with the risk of PSP.

185

186 **Methods**

187 *Study subjects and quality control*

188 All study subjects and WGS data are available on The National Institute on Aging Genetics of
189 Alzheimer's Disease Data Storage Site (NIAGADS)¹⁶ under Alzheimer's Disease Sequencing Project
190 (ADSP) Umbrella NG00067.v7¹⁷. We inferred ancestry of subjects by GRAF-pop¹⁸ and selected 4,618
191 subjects (1,797 cases and 2,821 controls) of European ancestry for analysis. WGS were performed at
192 30x coverage (e**Table 1**).

193 Among 4,618 samples, we filtered 183 samples with abnormally low reads mapped (aligned read
194 depth < 1.7x) to α , β or γ region (eFigure 2 in **Supplement**) and ten samples with high genotyping
195 missing rate (> 0.05). Next, 244 related samples inferred by KING¹⁹ (duplicates, monozygotic twins,

196 parent-offsprings, full-siblings, and 2nd degree relatives) were removed.

197 We used the 238-bp deletion between exons 9 and 10 of *MAPT*⁷ to determine the H1 and H2
198 haplotypes of each sample. The genotype calls of the 238-bp deletion were obtained from our previous
199 SV work²⁰. 75 subjects were removed due to missing or failed genotype of the 238-bp deletion. Given
200 the specification of H1/H2 genotype, determined by the 238 bp deletion, and the copy numbers of α , β
201 and γ , we can ascertain the ten structural forms (eFigure 1 in **Supplement**) in each individual. We
202 removed 30 individuals (eFigure 3 and eFigure 4 in **Supplement**) since their structural forms could not
203 be decided based on the copy numbers of α , β and γ . This discordance might be due to subjects carrying
204 undiscovered structural forms or genotyping errors on the copy numbers of α , β and γ . As a result, 4,076
205 subjects (**Table 1**; $N_{\text{PSP}} = 1,684$, $N_{\text{control}} = 2,392$) remained for statistical analyses in this study. Of the
206 1,684 individuals with PSP, 1,386 were autopsy confirmed.

207 **Table 1. Characteristics of PSP cases and controls**

	Overall (N = 4,076)	PSP (N = 1,684)	Control (N = 2,392)
Age^a (SD)	78.49 (8.50)	68.03 (8.17)	81.04 (6.37)
Sex (%)			
Female	2168 (53.19%)	739 (43.88%)	1429 (59.74%)
Male	1908 (46.81%)	945 (56.12%)	963 (40.26%)
H1/H2 status^b (%)			
H1H1	2958 (72.57%)	1511 (89.73%)	1447 (60.49%)
H1H2	975 (23.92%)	168 (9.98%)	807 (33.74%)
H2H2	143 (3.51%)	5 (0.30%)	138 (5.77%)
Structural forms of 17q21.31^c (%)			
H1β1γ1	2446 (30.00%)	1097 (32.57%)	1349 (28.20%)
H1β1γ2	1552 (19.04%)	739 (21.94%)	813 (16.99%)
H1β1γ3	987 (12.11%)	496 (14.73%)	491 (10.26%)
H1β1γ4	126 (1.55%)	65 (1.93%)	61 (1.28%)
H1β2γ1	1716 (21.05%)	774 (22.98%)	942 (19.69%)
H1β3γ1	64 (0.79%)	19 (0.56%)	45 (0.94%)
H2α1γ1	7 (0.09%)	1 (0.03%)	6 (0.13%)
H2α1γ2	99 (1.21%)	14 (0.42%)	85 (1.78%)
H2α2γ1	33 (0.40%)	2 (0.06%)	31 (0.65%)
H2α2γ2	1122 (13.76%)	161 (4.78%)	961 (20.09%)

208 ^a1,130 PSP cases and 111 controls have missing age.

209 ^bH1/H2 status was determined by the genotype of a 238-bp H2 tagging deletion⁷.

210 ^cStructural forms of 17q21.31 were inferred by expectation-maximization (EM) algorithm.

211 *Calling the copy numbers α , β and γ duplications from WGS*

212 The genomic coordinates on HG38 of α (chr17:46135415-46289349), β
213 (chr17:46087894-46356512), and γ (chr17:46289349-46707123) were obtained from two previous
214 studies^{14,15} (eFigure 1 in **Supplement**). Segmental duplications can introduce mapping challenges and
215 thus inaccurate calling of the number of copies²¹⁻²³. To address this, we removed segmental duplicated
216 regions inside the α , β and γ (eFigure 5 in **Supplement**) when calculating aligned read depth.
217 Subsequently, the copy numbers of α , β , and γ were obtained based on the aligned read depth on
218 chr17:46135415-46203287, chr17:46106189-46135415, and
219 chr17:46356512-46489410/chr17:46565081-46707123, respectively. Copies of α , β and γ were
220 genotyped by assessing aligned read depth within each 1 Kb bin on the specified regions using
221 CNVpytor (Version 1.3.1)²⁴. Then, we employed K-means²⁵ to assign an integer copy number for α , β
222 and γ for the 4,076 individuals.

223

224 *Validation of CNV calling*

225 To validate the copy numbers of α , β and γ called from WGS, 66 samples were genotyped using
226 TaqMan CNV assay. Overall, the copy number of α , β , or γ inferred by aligned read depth from WGS
227 were highly consistent (α , $R = 0.87$; γ , $R = 0.96$) with that from TaqMan assay (eFigure 6 in
228 **Supplement**). The experimental procedure was as follows: Copy number at the α region (Context
229 Sequence: TTAGTCAATTTCTTAGCCAACCCAT; chr17:46171656-46171680, GRCh38) was
230 determined using a predesigned TaqMan CNV assay (Applied Biosystems Part No. Hs01788222_cn).

231 Copy number at the γ region (Context Sequence: AGAAAAAAGCATTGACTCCAACCC;
232 chr17:46419867-46419891 and chr17:46637445-46637469, GRCh38) was determined using a custom
233 designed TaqMan CNV assay (Applied Biosystems; Forward Primer:
234 TGGCACAATGACCATCGAGATT, Reverse Primer: CTGCCATCTTGTCGGTGTCA, Reporter
235 Sequence: AAGGGTTGGAGTCAATGCTTTT). For the copy number assay reaction, 20 ng of genomic
236 DNA was combined with TaqMan Master Mix (Applied Biosystems Part No. 4371357), 20X TaqMan
237 CNV assay, and 20x RNase P TaqMan Copy Number Reference Assay (Applied Biosystems Part No.
238 4403328) in a total volume of 20ul. The DNA amplification and quantification were carried out in a
239 QuantStudio 12K Flex instrument (Applied Biosystems) in a 96 well format with the following program:
240 50°C 2min, 95°C 10min followed by 40 cycles of 95°C 15sec, 60°C 1min. The results were analyzed
241 using the TaqMan CopyCaller software (Version 2.0) (Applied Biosystems).

242

243 *Determine haplotypic contributions to diploid copy number*

244 For approximately sixty percent of the samples, only one combination of the structural forms
245 (eFigure 1 in **Supplement**) was possible based on the H1 and H2 genotypes, determined by the 238-bp
246 deletion, and the copy numbers of α , β and γ . For the rest of the samples, multiple haplotypic
247 combinations were possible. Therefore, we initially assigned an equal likelihood to all possible
248 haplotypic combinations that were consistent with the detected copy number of α , β , and γ . Then, the
249 following expectation-maximization (EM) loop described in the previous study¹⁴ were repeated: from
250 the probabilistic inferences of structural form of 17q21.31 in each sample, we estimated an allele

251 frequency for each structural form of 17q21.31; we then re-estimated the relative likelihood of each
252 combination of haplotypes in each sample, given the population-level allele frequency. In this way, we
253 intended to eliminate haplotypic combinations that are theoretically possible but extremely unlikely
254 given the apparent frequencies of haplotypes as estimated from the rest of the population. The revised
255 probabilistic estimates then allowed a new population-level estimate of haplotype frequencies. We
256 repeated this EM loop process until estimates of haplotype frequency converged. The allele frequency of
257 each structural form of 17q21.31 after convergence were showed in eFigure 1 in **Supplement**.

258

259 *Phasing for MAPT sub-haplotypes*

260 The six SNVs (rs1467967, rs242557, rs3785883, rs2471738, rs8070723, and rs7521)¹¹⁻¹³ on *MAPT*
261 were employed to defined the 26 *MAPT* sub-haplotypes (eTable 2 in **Supplement**). We phased the six
262 SNVs with other SNVs and indels in chr17:43000000-48000000 to determine the *MAPT* sub-haplotypes.
263 The SNV genotypes for the study subjects were called in our previous work²⁶. Variants were removed if
264 they were monomorphic, did not pass variant quality score recalibration, had an average read depth \geq
265 500, or if all calls have $DP < 10$ & $GQ < 20$. Individual calls with a $DP < 10$ or $GQ < 20$ were set to missing.
266 Then, common variants ($MAF > 0.01$) with $0.25 < ABHet < 0.75$ were phased using SHAPEIT4²⁷
267 (Version 4.2.2).

268

269 *Linkage disequilibrium between structural forms of 17q21.31 and MAPT sub-haplotypes*

270 To phase the structural forms of 17q21.31 together with *MAPT* sub-haplotypes, we encoded the

271 copy numbers of α , β and γ as multi-allelic CNVs by a series of surrogate bi-allelic markers with 0/1
272 alleles¹⁴ (eTable 3 in **Supplement**). Then, SHAPEIT4²⁷ (Version 4.2.2) were used for phasing the copy
273 numbers of α , β and γ together with SNVs/indels. SNVs and indels inside α , β , and γ regions
274 (chr17:46087000-46708000) were not included when phasing. After phasing, we calculated the linkage
275 disequilibrium (LD) between structural forms of 17q21.31 and *MAPT* sub-haplotypes.

276

277 *Statistical Analysis*

278 Statistical analyses were performed for the 4,076 individuals ($N_{\text{PSP}} = 1,684$, $N_{\text{control}} = 2,392$). For the
279 association of the copy numbers of α , β , and γ with PSP, logistic regression adjusting for sex and PC1-5
280 for population substructure was employed. Age was not adjusted in the regression model with following
281 considerations: first, more than half of the PSP cases have age missing (**Table 1**); second, controls
282 (average age, 81) was much older compared to PSP (average age, 63) and well over the mean age-of
283 onset for PSP which is 63 years²⁸. Individuals with the H2H2 genotype are imbalanced (5 cases, 138
284 controls) and with few cases, therefore, statistical analysis for this subgroup was not included.

285 To evaluate the association of the structural forms of 17q21.31 with PSP, each structural form with
286 allele frequency > 1% is compared with the rest of structural forms using logistic regression model
287 adjusting for sex and PC1-5. To evaluate the association of *MAPT* sub-haplotypes with PSP, each *MAPT*
288 sub-haplotypes with allele frequency > 1% was compared with the rest of sub-haplotypes using logistic
289 regression adjusting for sex and PC1-5.

290

291 **Results**

292 *The copy numbers of α , β , and γ and PSP risk*

293 The H1 and H2 haplotypes are the most prominent genetic risk factor for PSP. Individuals with the
294 H2 haplotype showed significantly lower risk of disease (OR, 0.19; 95%CI, 0.16-0.22; $P = 3.00 \times 10^{-79}$).
295 Structural forms of 17q21.31 can be characterized by three large duplications α , β , and γ ^{14,15}. However,
296 their specific contributions to the risk of PSP have not been carefully assessed. In this study, we first
297 evaluated whether the copy numbers of α , β , or γ are associated to the risk of PSP independently from
298 H1 and H2 (eFigure 7 in **Supplement**).

299 We found that each additional copy of γ was associated with 1.08 (95%CI, 1.02-1.15; $P = 0.014$)
300 fold of increased risk of PSP in H1H1 individuals and 1.29 (95%CI, 1.06-1.56; $P = 0.0096$) fold of
301 increased risk of PSP in H1H2 individuals (**Table 2**). The association of the copy number of γ with PSP
302 in H2H2 individuals was not evaluated since there were only five H2H2 PSP samples. On average, γ
303 was associated with 1.10 (95% CI, 1.04-1.17; $P = 0.0018$) fold of increased risk of PSP after adjusting
304 for sex, PC1-5, and allele count (0, 1, or 2) of the H2 haplotype (**Table 2**). Without adjusting for H2, the
305 effect of γ would be neglected (OR, 0.98; 95%CI, 0.93-1.04; $P = 0.60$, **Table. 2**) because the H2
306 haplotype has increased copies (usually two copies) of γ while displayed significantly lower risk of PSP.

307

308 **Table 2. Association between the copy numbers of α , β , γ and risk of PSP**

Model: Sex, PC1-5 (H1H1 carriers, N=2,958 (PSP = 1,511; Control = 1,447)	Model: Sex, PC1-5 (H1H2 carriers, N=975 (PSP = 168; Control = 807)
-----------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------

	OR (95% CI)	P	OR (95% CI)	P
α	0.91 (0.81-1.02)	0.11	0.81 (0.58-1.11)	0.20
β	0.91 (0.81-1.02)	0.11	0.79 (0.53-1.15)	0.23
γ	1.08 (1.02-1.15)	0.014*	1.29 (1.06-1.56)	0.0096*
Model: Sex, PC1-5		Model: Sex, PC1-5, H2		
(N = 4,076)		(N = 4,076)		
(PSP = 1,684; Control = 2,392)		(PSP = 1,684; Control = 2,392)		
	OR (95% CI)	P	OR (95% CI)	P
α	0.57 (0.52-0.63)	$< 2 \times 10^{-16}$ *	0.90 (0.81-1.00)	0.061
β	1.14 (1.03-1.27)	0.011*	0.90 (0.81-1.01)	0.064
γ	0.98 (0.93-1.04)	0.60	1.10 (1.04-1.17)	0.0018*

309 *Represents statistical significance (< 0.05)

310 We found no significant association for the copy numbers of α (OR, 0.9; 95%CI 0.81-1.00; $P =$
311 0.061) and β (OR, 0.9; 95%CI 0.81-1.01; $P = 0.064$) with PSP when adjusting the allele count (0, 1, or 2)
312 of H2 (**Table 2**); however, individuals with more copies of α and β showed slightly lower odds ratio for
313 PSP. Similarly, no significance was observed for the copy numbers of α and β when association analysis
314 was stratified by H1H1 or H1H2 genotype. Only under the regression model without adjusting H1 and
315 H2, we observed statistically significant association for the copy numbers of α ($P < 2 \times 10^{-16}$) and β ($P =$
316 0.011) with PSP. However, the observed significance mainly arises from their correlation with the H1
317 and H2 haplotypes, i.e., the increased copies (usually two copies) of α and the absence of β duplication
318 in the H2 haplotype.

319

320 *Structural forms of 17q21.31 and PSP risk*

321 We then evaluated whether the structural forms of 17q21.31, characterized by the α , β , and γ , show
 322 distinct effect on the risk of PSP. We found that the odds ratio for PSP increases from 1.21 (H1 β 1 γ 1,
 323 95%CI 1.10-1.33) to 1.57 (H1 β 1 γ 4, 95%CI 1.10-2.26) as the copy number of γ increases from one copy
 324 to four copies (**Table 3**). With an additional copy of β , H1 β 2 γ 1 (OR, 1.24; 95%CI 1.11-1.38; $P = 1.87 \times$
 325 10^{-4}) displayed similar risk compared to H1 β 1 γ 1 (OR, 1.21; 95%CI 1.10-1.33; $P = 5.47 \times 10^{-5}$) regarding
 326 PSP. This reaffirmed our finding that the copy number of γ was associated with increased risk of PSP
 327 independently from H1 and H2, and β was not associated with the risk of PSP (**Table 2**; eFigure 7 in
 328 **Supplement**). Besides, all structural forms with H1 background displayed increased risk of PSP and all
 329 structural forms with H2 background displayed decreased risk of PSP (**Table 3**).

330

331 **Table 3. Structural forms of 17q21.31 and the risk of PSP**

Structural forms	Frequency (%)		Odds ratio	P
	PSP (N = 1,684)	Control (N = 2,392)		
H1 β 1 γ 1	32.57	28.20	1.21 (1.10-1.33)	5.47×10^{-5}
H1 β 1 γ 2	21.94	16.99	1.29 (1.16-1.43)	1.35×10^{-6}
H1 β 1 γ 3	14.73	10.26	1.45 (1.27-1.65)	3.94×10^{-8}
H1 β 1 γ 4	1.93	1.28	1.57 (1.10-2.26)	1.35×10^{-2}
H1 β 2 γ 1	22.98	19.69	1.24 (1.11-1.38)	1.87×10^{-4}
H2 α 1 γ 2	0.42	1.78	0.23 (0.12-0.40)	5.94×10^{-7}
H2 α 2 γ 2	4.78	20.09	0.19 (0.16-0.23)	$< 2 \times 10^{-16}$

332 Haplotypes in less than 1% of individuals were excluded.

333 Odds ratio and P value were from logistic regression adjusting for PC1-5 and Sex.

334

335 *Structural forms of 17q21.31 and MAPT sub-haplotypes*

336 According to the LD structure in *MAPT* gene (~150 Kb), 26 *MAPT* sub-haplotypes can be
 337 determined by six haplotype-tagging SNVs¹¹⁻¹³ (eTable 2 in Supplement). We confirmed the
 338 association of H1c (OR 1.79; 95%CI 1.58-2.04; $P = 1.84 \times 10^{-19}$), H1d (OR 1.52; 95%CI 1.29-1.79; $P =$
 339 3.89×10^{-7}), and H1o (OR 2.88; 95%CI 2.15-3.89; $P = 2.77 \times 10^{-12}$) with PSP (Table 4). Moreover, H1g
 340 (OR 1.46; 95%CI 1.07-1.98; $P = 0.016$), which was significant, and H1h (OR 1.36; 95%CI 1.10-1.69; P
 341 $= 0.0053$), which was not significant in the previous study¹¹, were both nominal significant in our
 342 analysis.

343 **Table 4. *MAPT* sub-haplotypes defined by six SNVs and the risk of PSP**

Haplotype	Sub-haplotype Frequency (%)		OR	P
	PSP (N = 1,684)	Control (N = 2,392)		
H1b	16.92	16.99	1.01 (0.90-1.14)	0.84
H1c**	19.6	11.98	1.79 (1.58-2.04)	1.84×10^{-19}
H1d**	10.39	7.09	1.52 (1.29-1.79)	3.89×10^{-7}
H1e	8.76	8.07	1.12 (0.95-1.32)	0.17
H1g*	2.67	1.80	1.46 (1.07-1.98)	0.016
H1h*	5.23	4.03	1.36 (1.10-1.69)	0.0053
H1i	4.69	4.08	1.17 (0.94-1.46)	0.15
H1j	1.28	1.21	1.09 (0.72-1.64)	0.68
H1l	2.91	3.22	0.92 (0.71-1.20)	0.55
H1m	2.11	2.07	1.08 (0.78-1.47)	0.64
H1o**	4.13	1.53	2.88 (2.15-3.89)	2.77×10^{-12}
H1p	1.07	1.36	0.80 (0.52-1.21)	0.30
H1q	1.22	0.86	1.45 (0.92-2.26)	0.11
H1r	1.16	1.30	0.92 (0.60-1.39)	0.69
H1u	2.64	2.34	1.16 (0.86-1.54)	0.33
H1x	1.43	1.36	0.98 (0.67-1.44)	0.93
H1y	1.54	1.51	1.01 (0.70-1.44)	0.98
H1z	1.40	1.00	1.41 (0.93-2.14)	0.11


344 *MAPT* sub-haplotypes in less than 1% of individuals were excluded.

345 *Represents *MAPT* sub-haplotypes with a $P \leq 0.05$ (nominal significant)

346 **Represents *MAPT* sub-haplotypes with a $P \leq 0.0028$ (Bonferroni corrected P cutoff for the 18 test
347 performed)

348

349 We examined the relationship between the structural forms of 17q21.31 (~1.5 Mb) and *MAPT*
350 sub-haplotypes (~150 Kb) through LD analysis. We identified two pairs with $R^2 > 0.1$ (eTable 4 in
351 **Supplement**): H1 β 1 γ 3 and H1c ($R^2 = 0.31$) and H1 β 2 γ 1 and H1b ($R^2 = 0.29$). This was confirmed by
352 the fact that 70% of H1 β 1 γ 3 are H1c and 56% of H1 β 2 γ 1 are H1b (**Fig. 1A**). Moreover, with additional
353 copies of γ in the H1, the proportion of *MAPT* sub-haplotypes with increased risk of PSP (i.e., H1c, H1d,
354 H1g, H1h, and H1o) increases from 34% (H1 β 1 γ 1) to 77% (H1 β 1 γ 4) (**Fig. 1A**). In contrast, the
355 proportion of *MAPT* sub-haplotypes with increased risk of PSP drops from 34% (H1 β 1 γ 1) to 11%
356 (H1 β 2 γ 1) with an additional copy of β (**Fig. 1A**). In individuals with H1H2 genotypes, no phasing is
357 needed before comparison, therefore, the association between the structural forms of 17q21.31 and
358 *MAPT* sub-haplotypes can be observed directly without phasing (**Fig. 1B**).



359

360 **Fig. 1: Structural forms of 17q21.31 and *MAPT* sub-haplotypes**

361 Structural forms of 17q.21.31 in less than 1% of individuals were excluded. Structural forms with H2
 362 background are also excluded since there is only one *MAPT* sub-haplotypes for H2. The number above
 363 each bar is the total number of *haplotypes* for the specific structural form of 17q21.31 and the
 364 percentage that are also *MAPT* sub-haplotypes (H1o, H1c, H1d, H1g, H1h) associated with increased
 365 risk of PSP. Besides, the percentage of H1β1γ3 that is H1c and the percentage of of H1β2γ1 that is H1b
 366 are displayed. **A.** In phased haplotypes from all samples, the proportion of *MAPT* sub-haplotypes in each
 367 structural form of 17q21.31. **B.** In H1H2 individuals, the proportion of *MAPT* sub-haplotypes in each
 368 structural form of 17q21.31.

369

370 **Discussion**

371 The H1 and H2 haplotypes on 17q21.31 is the strongest genetic risk factor for PSP⁷. The *MAPT*
 372 gene inside H1 and H2 showed haplotypic-specific expression and was considered as the possible cause

373 of the association^{29,30}. Therefore, previous studies have been focused on variants and haplotypic
374 structures inside *MAPT* and identified sub-haplotypes H1c, H1d, H1o, and H1g, which displayed
375 increased risk of PSP^{11,13}. In this study, we went beyond *MAPT* gene (~150 Kb) and evaluated the
376 association of the structural forms of 17q21.31 (~1.5 Mb), characterized by large duplications α , β , and γ ,
377 with the risk PSP. We found that the copy number of γ duplication was associated with increased risk of
378 PSP and structural forms with γ duplication (such as H1 β 1 γ 2, H1 β 1 γ 3, and H1 β 1 γ 4) had a higher odds
379 ratio for PSP compared to H1 β 1 γ 1. This is in accordance with the fact that structural forms with
380 additional copies of γ (from H1 β 1 γ 1 to H1 β 1 γ 4) tended to have more *MAPT* sub-haplotypes with a
381 significant risk to PSP (i.e., H1c, H1d, H1o, H1g, H1h). Overall, this study provided a first analysis on
382 the association of structural forms of 17q21.31 with the risk of PSP and *MAPT* sub-haplotypes.

383 It should be noted that the copy numbers of α , β , and γ are correlated with H1 and H2. When
384 performing the association of the copy numbers of α , β , and γ with PSP in individuals with European
385 ancestry, previous studies demonstrated that the 205-Kb β region can only duplicate in the H1 haplotype,
386 the smaller 155-Kb α region but not the entire β region duplicates in the H2 haplotype, and the 210-Kb γ
387 region usually duplicates only once in the H2 haplotype (eFigure 1 in **Supplement**)^{15,31}. Therefore, it is
388 important to adjust the status of H1 and H2 and split analysis by individuals with H1H1 and H1H2
389 genotypes when performing the association of α , β , and γ with PSP. In terms of genomic position, the α
390 region is included in β region, and parts of β and γ are overlapping with each other (eFigure 1 in
391 **Supplement**). When performing the association of α with PSP, we considered whenever there was a β
392 duplication there was also a α duplication as α region is included in β . Considering these factors, we

393 found that only γ is independently associated with risk of PSP, and the associations of α and β with PSP
394 are due to their correlation with H1 and H2.

395 The influence of structural forms of 17q21.31 on the risk of PSP has never been examined before. In
396 this study, we found that all structural forms with H1 background were association with increased with
397 of PSP. Particularly, H1 with additional γ copies (H1 β 1 γ 2, H1 β 1 γ 3, and H1 β 1 γ 4) displayed a higher
398 odds ratio for PSP compared to H1 β 1 γ 1. In previous studies of *MAPT* sub-haplotypes, only a few
399 sub-haplotypes (i.e., H1c, H1d, H1o, and H1g) were associated with increased risk of PSP while other
400 sub-haplotypes displayed no differences against the rest of the population^{11,13}. We replicated the
401 association of H1c, H1d, H1o and H1g with PSP and identified H1h with nominal significance.
402 Furthermore, we showed that the H1 haplotype with additional γ copies had more *MAPT* sub-haplotypes
403 that have higher risk of PSP (H1c, H1d, H1o, H1g and H1h), the proportion of *MAPT* sub-haplotypes
404 associated with PSP increased from 34% in H1 β 1 γ 1 to 77% in H1 β 1 γ 4.

405 **Limitations**

406 Despite our finding of the importance of the copy number of γ duplication in the risk of PSP, there
407 are a few limitations in the current study. First, all our PSP samples are of European ancestry. It is
408 important to collect samples from other ancestries to validate the discovery in a genetically diverse
409 background. Second, not all PSP cases are pathologically confirmed: of the 1,684 individuals with PSP,
410 1,386 were autopsy confirmed. Finally, the association analysis needed to be replicated in an
411 independent dataset. Currently, the available resource for whole genome sequencing data in PSP is
412 limited. Therefore, future study focusing on α , β , and γ regions using CNV array to replicate the findings

413 in a large independent cohorts might be helpful.

414

415 **Conclusions**

416 In this study of 4076 subjects ($N_{\text{PSP}} = 1,684$, $N_{\text{control}} = 2,392$), we found that γ duplication was
417 associated with increased risk (OR, 1.10; 95% CI, 1.04-1.17; $P = 0.0018$) of PSP. In accordance with
418 this finding, the structural forms with additional copies of γ (H1 β 1 γ 2 [OR, 1.29; 95%CI 1.16-1.43; $P =$
419 1.35×10^{-6}], H1 β 1 γ 3 [OR, 1.45; 95%CI 1.27-1.65; $P = 3.94 \times 10^{-8}$], H1 β 1 γ 4[OR, 1.57; 95%CI 1.10-2.26;
420 $P = 1.35 \times 10^{-2}$]) showed higher odds ratio for PSP compared to H1 β 1 γ 1 (OR, 1.21; 95%CI 1.10-1.33; P
421 $= 5.47 \times 10^{-5}$) and had higher proportion of *MAPT* sub-haplotypes associated with increased risk of PSP
422 (i.e., H1c, H1d, H1g, H1o, and H1g).

423

424 **Declarations**

425 *Ethics approval and consent to participate*

426

427 *Consent for publication*

428 Not applicable.

429

430 *Availability of data and materials*

431 NIAGADS Data Sharing Service (<https://dss.niagads.org/>)

432

433 *Competing interests*

434 Laura Molina-Porcel received income from Biogen as a consultant in 2022. Gesine Respondek is
435 now employed by Roche (Hoffmann-La Roche, Basel, Switzerland) since 2021. Her affiliation whilst
436 completing her contribution to this manuscript was German Center for Neurodegenerative Diseases
437 (DZNE), Munich, Germany. Thomas G Beach is a consultant for Aprinoia Therapeutics and a Scientific
438 Advisor and stock option holder for Vivid Genomics. Huw Morris is employed by UCL. In the last 12
439 months he reports paid consultancy from Roche, Aprinoia, AI Therapeutics and Amylyx; lecture
440 fees/honoraria - BMJ, Kyowa Kirin, Movement Disorders Society. Huw Morris is a co-applicant on a
441 patent application related to C9ORF72 - Method for diagnosing a neurodegenerative disease
442 (PCT/GB2012/052140). Giovanni Coppola is currently an employee of Regeneron Pharmaceuticals.
443 Alison Goate serves on the SAB for Genentech and Muna Therapeutics.

444

445 *Funding*

446 This work was supported by NIH 5UG3NS104095, the Rainwater Charitable Foundation, and
447 CurePSP. HW and PLC are supported by RF1-AG074328, P30-AG072979, U54-AG052427 and
448 U24-AG041689. TSC is supported by NIH K08AG065519 and the Larry L Hillblom Foundation
449 2021-A-005-SUP. YQS, AT, and JYT are supported by RF1-AG074328. KF was supported by CurePSP
450 685-2023-06-Pathway and K01 AG070326. MG is supported by P30 AG066511. BFG and KLN are
451 supported by P30 AG072976 and R01 AG080001. TGB and GES are supported by P30AG072980. IR is
452 supported by 2R01AG038791-06A, U01NS100610, R25NS098999, U19 AG063911-1 and
453 1R21NS114764-01A1. OR is support by U54 NS100693. DG is supported by P30AG062429. ALB is

454 supported by U19AG063911, R01AG073482, R01AG038791, and R01AG071756. BLM is supported
455 by P01 AG019724, R01 AG057234 and P0544014. VMV is supported by P01-AG-066597,
456 P01-AG-017586. HRM is supported by CurePSP, PSPA, MRC, and Michael J Fox Foundation. RDS is
457 supported by CurePSP, PSPA, and Reta Lila Weston Trust. JFC is supported by R01 AG054008, R01
458 NS095252, R01 AG060961, R01 NS086736, R01 AG062348, P30 AG066514, the Rainwater Charitable
459 Foundation / Tau Consortium, Karen Strauss Cook Research, and Scholar Award, Stuart Katz & Dr. Jane
460 Martin. AMG is supported by the Tau Consortium and U54-NS123746. YYL is supported by
461 U54-AG052427; U24-AG041689. LSW is supported by U01AG032984, U54AG052427, and
462 U24AG041689. GUH was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research
463 Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for
464 Systems Neurology (EXC 2145 SyNergy - ID 390857198); Deutsche Forschungsgemeinschaft (DFG,
465 HO2402/18-1 MSAomics); German Federal Ministry of Education and Research (BMBF, 01KU1403A
466 EpiPD; 01EK1605A HitTau; 01DH18025 TauTherapy). DHG is supported by 3UH3NS104095, Tau
467 Consortium. WPL is supported by RF1-AG074328; P30-AG072979; U54-AG052427; U24-AG041689.
468 Cases from Banner Sun Health Research Institute were supported by the NIH (U24 NS072026, P30
469 AG19610 and P30AG072980), the Arizona Department of Health Services (contract 211002, Arizona
470 Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011,
471 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for
472 Parkinson's Research. The Mayo Clinic Brain Bank is supported through funding by NIA grants P50
473 AG016574, CurePSP Foundation, and support from Mayo Foundation.

474

475 *Acknowledgements*

476 This project is supported by CurePSP, courtesy of a donation from the Morton and Marcine
477 Friedman Foundation. We are indebted to the Biobanc-Hospital Clinic-FRCB-IDIBAPS and Center for
478 Neurodegenerative Disease Research at Penn for samples and data procurement. The PSP genetics study
479 group is a multisite collaboration including: German Center for Neurodegenerative Diseases (DZNE),
480 Munich; Department of Neurology, LMU Hospital, Ludwig-Maximilians-Universität (LMU), Munich,
481 Germany (Franziska Hopfner, Günter Höglinger); German Center for Neurodegenerative Diseases
482 (DZNE), Munich; Center for Neuropathology and Prion Research, LMU Hospital,
483 Ludwig-Maximilians-Universität (LMU), Munich, Germany (Sigrun Roeber, Jochen Herms);
484 Justus-Liebig-Universität Gießen, Germany (Ulrich Müller); MRC Centre for Neurodegeneration
485 Research, King's College London, London, UK (Claire Troakes); Movement Disorders Unit, Neurology
486 Department and Neurological Tissue Bank and Neurology Department, Hospital Clínic de Barcelona,
487 University of Barcelona, Barcelona, Catalonia, Spain (Ellen Gelpi; Yaroslau Compta); Department of
488 Neurology and Netherlands Brain Bank, Erasmus Medical Centre, Rotterdam, The Netherlands (John C.
489 van Swieten); Division of Neurology, Royal University Hospital, University of Saskatchewan, Canada
490 (Alex Rajput); Australian Brain Bank Network in collaboration with the Victorian Brain Bank Network,
491 Australia (Fairlie Hinton), Department of Neurology, Hospital Ramón y Cajal, Madrid, Spain (Justo
492 García de Yébenes). The acknowledgement of PSP cohorts is listed below, whereas the
493 acknowledgement of ADSP cohorts for control samples can be found in the supplementary materials.

494 The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of
495 the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and
496 NINDS. The data used for the analyses described in this manuscript were obtained from:
497 <https://gtexportal.org/home/datasets> the GTEx Portal on 1/27/2022. We also thank to Drs. Murray
498 Grossman and Hans Kretzschmar for their valuable contribution to this work.

499 AMP-AD (sa000011) data: Mayo RNAseq Study- Study data were provided by the following sources:

500 The Mayo Clinic Alzheimer's Disease Genetic Studies, led by Dr. Nilufer Ertekin-Taner and Dr. Steven
501 G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the
502 Mayo Clinic Alzheimer's Disease Research Center, and the Mayo Clinic Brain Bank. Data collection
503 was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01
504 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949,
505 NINDS grant R01 NS080820, CurePSP Foundation, and support from Mayo Foundation. Study data
506 includes samples collected through the Sun Health Research Institute Brain and Body Donation Program
507 of Sun City, Arizona. The Brain and Body Donation Program is supported by the National Institute of
508 Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's
509 Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's
510 Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's
511 Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and
512 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's
513 Research.

514 PSP-NIH-CurePSP-Tau (sa000015) data: This project was funded by the NIH grant UG3NS104095 and
515 supported by grants U54NS100693 and U54AG052427. Queen Square Brain Bank is supported by the
516 Reta Lila Weston Institute for Neurological Studies and the Medical Research Council UK. The Mayo
517 Clinic Florida had support from a Morris K. Udall Parkinson's Disease Research Center of Excellence
518 (NINDS P50 #NS072187), CurePSP and the Tau Consortium. The samples from the University of
519 Pennsylvania are supported by NIA grant P01AG017586.

520 PSP-CurePSP-Tau (sa000016) data: This project was funded by the Tau Consortium, Rainwater
521 Charitable Foundation, and CurePSP. It was also supported by NINDS grant U54NS100693 and NIA
522 grants U54NS100693 and U54AG052427. Queen Square Brain Bank is supported by the Reta Lila
523 Weston Institute for Neurological Studies and the Medical Research Council UK. The Mayo Clinic
524 Florida had support from a Morris K. Udall Parkinson's Disease Research Center of Excellence (NINDS
525 P50 #NS072187), CurePSP and the Tau Consortium. The samples from the University of Pennsylvania
526 are supported by NIA grant P01AG017586. Tissues were received from the Victorian Brain Bank,
527 supported by The Florey Institute of Neuroscience and Mental Health, The Alfred and the Victorian
528 Forensic Institute of Medicine and funded in part by Parkinson's Victoria and MND Victoria. We are
529 grateful to the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona for
530 the provision of human biological materials (or specific description, e.g. brain tissue, cerebrospinal
531 fluid). The Brain and Body Donation Program is supported by the National Institute of Neurological
532 Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and
533 Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core

534 Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research
535 Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the
536 Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's Research.
537 Biomaterial was provided by the Study Group DESCRIBE of the Clinical Research of the German
538 Center for Neurodegenerative Diseases (DZNE).

539 PSP_UCLA (sa000017) data: Thank to the AL-108-231 investigators, Adam L Boxer, Anthony E Lang,
540 Murray Grossman, David S Knopman, Bruce L Miller, Lon S Schneider, Rachelle S Doody, Andrew
541 Lees, Lawrence I Golbe, David R Williams, Jean-Cristophe Corvol, Albert Ludolph, David Burn,
542 Stefan Lorenzl, Irene Litvan, Erik D Roberson, Günter U Höglinger, Mary Koestler, Clifford R Jack Jr,
543 Viviana Van Deerlin, Christopher Randolph, Iryna V Lobach, Hilary W Heuer, Illana Gozes, Lesley
544 Parker, Steve Whitaker, Joe Hirman, Alistair J Stewart, Michael Gold, and Bruce H Morimoto.

545 *Authors' information*

546

547 *Authors' contribution*

548 Study design: TSC, DD, GUH, JYT, DHG, GDS, and WPL. Sample collection, brain biospecimens,
549 and neuropathological examinations: TSC, CM, LM, AR, PPDD, NLB, MG, LDK, JCVS, ED, BFG,
550 KLN, CT, JGdY, ARG, TM, WHO, GR, UM, FH, TA, SR, PP, AB, AD, ILB, TGC, GES, LNH, IL, RR,
551 OR, DG, ALB, BLM, WWS, VMVD, EBL, CLW, HM, JH, RdS, JFC, AMG, GC, and DHG. Genotype
552 or phenotype acquisition: HW, TSC, VP, LVB, KF, AN, LSW, DHG, GDS, and WPL. Variant detection
553 and variant quality check: HW, TSC, VP, LVB, KF, YYL, and WPL. Statistical analyses and

554 interpretation of results: HW, YQS, AT, TSC, KF, AN, JYT, DHG, GDS, and WPL. Experimental
555 validation: BAD and PLC. Draft of the manuscript: HW, GDS, and WPL. All authors read, critically
556 revised, and approved the manuscript.

557 **References**

- 558 1. Armstrong RA. Visual signs and symptoms of progressive supranuclear palsy. *Clin Exp Optom.*
559 2011;94(2):150-160. doi:10.1111/j.1444-0938.2010.00504.x
- 560 2. Lukic MJ, Respondek G, Kurz C, et al. Long-Duration Progressive Supranuclear Palsy: Clinical
561 Course and Pathological Underpinnings. *Ann Neurol.* 2022;92(4):637-649.
- 562 3. Ali F, Martin PR, Botha H, et al. Sensitivity and specificity of diagnostic criteria for progressive
563 supranuclear palsy. *Mov Disord.* 2019;34(8):1144-1153.
- 564 4. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for
565 Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). *Neurology.*
566 1994;44(11):2015-2015.
- 567 5. Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive
568 supranuclear palsy. *Acta Neuropathol (Berl).* 2020;140(2):99-119. doi:10.1007/s00401-020-02158-2
- 569 6. Stamelou M, Respondek G, Giagkou N, Whitwell JL, Kovacs GG, Höglinger GU. Evolving
570 concepts in progressive supranuclear palsy and other 4-repeat tauopathies. *Nat Rev Neurol.*
571 2021;17(10):601-620. doi:10.1038/s41582-021-00541-5
- 572 7. Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with
573 progressive supranuclear palsy. *Hum Mol Genet.* 1999;8(4):711-715.
- 574 8. Höglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk
575 of the tauopathy progressive supranuclear palsy. *Nat Genet.* 2011;43(7):699-705.
- 576 9. Wang H, Chang TS, Dombroski BA, et al. Whole-Genome Sequencing Analysis Reveals New
577 Susceptibility Loci and Structural Variants Associated with Progressive Supranuclear Palsy. *medRxiv.*
578 Published online 2023:2023-12.
- 579 10. Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of τ in
580 progressive supranuclear palsy. *Ann Neurol.* 1997;41(2):277-281. doi:10.1002/ana.410410222
- 581 11. Heckman MG, Brennan RR, Labbé C, et al. Association of MAPT subhaplotypes with risk of
582 progressive supranuclear palsy and severity of tau pathology. *JAMA Neurol.* 2019;76(6):710-717.
- 583 12. Heckman MG, Kasanuki K, Brennan RR, et al. Association of MAPT H1 subhaplotypes with
584 neuropathology of lewy body disease. *Mov Disord.* 2019;34(9):1325-1332. doi:10.1002/mds.27773
- 585 13. Pittman AM, Myers AJ, Abou-Sleiman P, et al. Linkage disequilibrium fine mapping and haplotype

- 586 association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration.
587 *J Med Genet.* 2005;42(11):837-846.
- 588 14. Boettger LM, Handsaker RE, Zody MC, McCarroll SA. Structural haplotypes and recent evolution
589 of the human 17q21. 31 region. *Nat Genet.* 2012;44(8):881-885.
- 590 15. Steinberg KM, Antonacci F, Sudmant PH, et al. Structural diversity and African origin of the 17q21.
591 31 inversion polymorphism. *Nat Genet.* 2012;44(8):872-880.
- 592 16. Kuzma A, Valladares O, Cweibel R, et al. NIAGADS: The NIA Genetics of Alzheimer's Disease
593 Data Storage Site. *Alzheimers Dement.* 2016;12(11):1200-1203. doi:10.1016/j.jalz.2016.08.018
- 594 17. Beecham GW, Bis JC, Martin ER, et al. The Alzheimer's Disease Sequencing Project: study design
595 and sample selection. *Neurol Genet.* 2017;3(5).
- 596 18. Jin Y, Schaffer AA, Feolo M, Holmes JB, Kattman BL. GRAF-pop: a fast distance-based method to
597 infer subject ancestry from multiple genotype datasets without principal components analysis. *G3*
598 *Bethesda Md.* 2019;9(8):2447-2461.
- 599 19. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship
600 inference in genome-wide association studies. *Bioinformatics.* 2010;26(22):2867-2873.
- 601 20. Wang H, Dombroski BA, Cheng PL, et al. Structural Variation Detection and Association Analysis
602 of Whole-Genome-Sequence Data from 16,905 Alzheimer's Diseases Sequencing Project Subjects.
603 *medRxiv.* Published online 2023.
- 604 21. Cantsilieris S, Western PS, Baird PN, White SJ. Technical considerations for genotyping
605 multi-allelic copy number variation (CNV), in regions of segmental duplication. *BMC Genomics.*
606 2014;15(1):329. doi:10.1186/1471-2164-15-329
- 607 22. Handsaker RE, Van Doren V, Berman JR, et al. Large multiallelic copy number variations in humans.
608 *Nat Genet.* 2015;47(3):296-303.
- 609 23. Sharp AJ, Locke DP, McGrath SD, et al. Segmental duplications and copy-number variation in the
610 human genome. *Am J Hum Genet.* 2005;77(1):78-88.
- 611 24. Suvakov M, Panda A, Diesh C, Holmes I, Abyzov A. CNVpytor: a tool for copy number variation
612 detection and analysis from read depth and allele imbalance in whole-genome sequencing.
613 *Gigascience.* 2021;10(11):giab074.
- 614 25. Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine learning in Python. *J Mach*
615 *Learn Res.* 2011;12:2825-2830.

- 616 26. Lee WP, Choi SH, Shea MG, et al. Association of Common and Rare Variants with Alzheimer's
617 Disease in over 13,000 Diverse Individuals with Whole-Genome Sequencing from the Alzheimer's
618 Disease Sequencing Project. *medRxiv*. Published online 2023:2023-09.
- 619 27. Delaneau O, Zagury JF, Robinson MR, Marchini JL, Dermitzakis ET. Accurate, scalable and
620 integrative haplotype estimation. *Nat Commun*. 2019;10(1):5436.
- 621 28. Rajput A, Rajput AH. Progressive Supranuclear Palsy: Clinical Features, Pathophysiology and
622 Management. *Drugs Aging*. 2001;18(12):913-925. doi:10.2165/00002512-200118120-00003
- 623 29. Rademakers R, Melquist S, Cruts M, et al. High-density SNP haplotyping suggests altered
624 regulation of tau gene expression in progressive supranuclear palsy. *Hum Mol Genet*.
625 2005;14(21):3281-3292.
- 626 30. Caffrey TM, Joachim C, Paracchini S, Esiri MM, Wade-Martins R. Haplotype-specific expression of
627 exon 10 at the human MAPT locus. *Hum Mol Genet*. 2006;15(24):3529-3537.
- 628 31. Sudmant PH, Kitzman JO, Antonacci F, et al. Diversity of human copy number variation and
629 multicopy genes. *Science*. 2010;330(6004):641-646.